- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05287945
Undersøgelse af Orellanin i metastatisk klarcellet eller papillært nyrecellekarcinom
Et fase I/II, åbent, enkeltarmsstudie om sikkerhed, tolerabilitet og antitumoreffektivitet af orellaninbehandling hos patienter med metastatisk klarcellet eller papillært nyrecellecarcinom
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.
Studieoversigt
Detaljeret beskrivelse
This is an open, non-controlled, phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 75 patients and is conducted in 3 parts. The study will consist of 3 parts: Part A - an intra-patient dose escalation part, followed by a dose exposure (Part B), followed by a dose expansion (Part C).
Part A, which is now closed, used an intra patient dose escalation design to evaluate safety across multiple dose levels.
The study is currently in Part B, an exposure based dose escalation phase. Patients may be enrolled into either a 24 hour or a 72 hour exposure cohort. Exposure duration is defined by the timing of hemodialysis, as elimination of orellanine occurs primarily through dialysis initiated after infusion. The starting dose for Part B is 0.38 mg/kg, and the total dose per treatment cycle is limited to 2.5 mg/kg, including any replacement doses. A minimum of three patients will be enrolled in each cohort, and escalation to longer exposure durations occurs only after safety evaluation.
Part C is a planned dose expansion phase to further characterize safety and explore preliminary antitumor activity at the selected dose and exposure level.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Hanjing Xie, Ph.D.
- Telefonnummer: +46737031615
- E-mail: hanjing.xie@oncorena.com
Undersøgelse Kontakt Backup
- Navn: Oncorena Study General Inquiries
- E-mail: oncorella1@oncorena.com
Studiesteder
-
-
California
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- University of California Irvine
-
Kontakt:
- Nataliya Mar, M.D.
- Telefonnummer: 714-456-5153
- E-mail: marn@hs.uci.edu
-
Ledende efterforsker:
- Nataliya Mar, M.D.
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Stanford
-
Kontakt:
- Sandhya Srinivas, M.D.
- Telefonnummer: 650-498-6000
- E-mail: sandysri@stanford.edu
-
Ledende efterforsker:
- Sandhya Srinivas, MD
-
San Francisco, California, Forenede Stater, 94158
- Rekruttering
- University of California San Francisco
-
Kontakt:
- Arpita Desai, M.D.
- Telefonnummer: 415-476-4616
- E-mail: arpita.desai@ucsf.edu
-
Ledende efterforsker:
- Arpita Desai, M.D.
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63130
- Rekruttering
- Washington University in St. Louis
-
Ledende efterforsker:
- Melissa Reimers, MD
-
Kontakt:
- Melissa Reimers, M.D.
- Telefonnummer: 314-273-3713
- E-mail: mreimers@wustl.edu
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Rekruttering
- Roswell Park Comprehensive
-
Ledende efterforsker:
- Saby George, MD
-
Kontakt:
- Telefonnummer: 8313 M.D. 716-845-2300
- E-mail: Saby.George@roswellpark.org
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- University of Texas - MD Anderson Cancer Center
-
Kontakt:
- Nizar Tannir, M.D.
- Telefonnummer: 713-563-7265
- E-mail: ntannir@mdanderson.org
-
Ledende efterforsker:
- Nizar Tannir, M.D.
-
-
-
-
-
Villejuif, Frankrig, 94805
- Rekruttering
- Institut de Cancerologie Gustave-Roussy
-
Kontakt:
- Christophe Massard, M.D., Ph.D
- Telefonnummer: +33142114211
- E-mail: Christophe.massard@gustaveroussy.fr
-
Ledende efterforsker:
- Christophe Massard, M.D., Ph.D.
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Rekruttering
- START Lisbon - Hospital de Santa Maria Av
-
Kontakt:
- Andre Mansinho, M.D.
- Telefonnummer: +351 210 405 907
- E-mail: andre.mansinho@startlisbon.com
-
Ledende efterforsker:
- Andre Mansinho, M.D.
-
-
-
-
-
Lleida, Spanien, 25004
- Rekruttering
- Clinica Mi Nova Alianca
-
Kontakt:
- Santiago Viteri, M.D., Ph.D.
- Telefonnummer: + 34 932287445
- E-mail: santiago.viteri@pratia.com
-
Ledende efterforsker:
- Santiago Viteri, M.D.
-
-
-
-
-
Stockholm, Sverige
- Rekruttering
- Karolinska University Hospital
-
Ledende efterforsker:
- Jeffrey Yachnin
-
Kontakt:
- Jeffrey Yachnin
- Telefonnummer: +46812370000
- E-mail: jeffrey.yachnin@regionstockholm.se
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
-
Has provided written informed consent.
-
Has a diagnosis of histologically confirmed advanced ccRCC or pRCC. No conventional therapy is available or considered appropriate by the treating physician or is declined by the patient.
-
For patients in the expansion portion of the study only: Measurable disease per RECIST version 1.1 criteria.
-
ECOG performance status of 0 - 2.
-
Age ≥18 years.
-
Life expectancy ≥3 months.
-
Has acceptable haematologic laboratory values defined as:
- Neutrophils ≥1.5 × 10^9/L, without growth factor stimulation within 3 weeks prior to the blood test;
- Platelets ≥100 × 10^9/L;
- Haemoglobin ≥5.6 mmol/L (~90 g/L). Use of erythropoietin or blood transfusions are permitted.
-
Has acceptable liver laboratory values defined as:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN for patients with liver metastases
- Total bilirubin ≤1.5 × ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 × ULN
- For patients diagnosed with Gilbert's syndrome, total bilirubin ≤2 × ULN is acceptable.
-
Must be on chronic hemodialysis (on a consistent regimen for the previous three months, with allowance for intermittent treatments as required for volume overload).
-
The patient's treating nephrologist and oncologist agree that the prospect of loss of remaining renal function resulting from this treatment will not significantly change the patient's future and chronic dialysis treatment.
-
Female patients of child-bearing potential and male patients must agree to use 2 forms of highly effective contraception for the duration of study treatment and after the last dose of orellanine for at least 3 months for males and 6 months for females.
-
For females of child-bearing potential, a negative serum pregnancy test at screening.
-
Patients who are willing and able to comply with travel requirements, scheduled visits, treatment schedule, efficacy assessments, laboratory tests, and other study procedures.
Exclusion criteria:
- Diagnosis of any other malignancy within 2 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, superficial melanoma, or carcinoma in situ of the breast or of the cervix, or low grade (Gleason 7 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g., surgery, radiation, or castration)
- Radiotherapy within 2 weeks before first dose.
- Immuno-oncology therapy (IO) given in the last six (6) months prior to enrolment
- Other systemic anti-cancer therapy within 2 weeks before first dose.
- Has not recovered from AEs due to prior anti-cancer medications to at least grade 1 by CTCAE version 5.0 (except for alopecia and grade 2 neuropathy).
- Has received any other investigational product within 4 weeks before first dose.
- Pregnant or breastfeeding women.
- Uncontrolled medical condition including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, or would, in the opinion of the investigator, place the patient at increased risk.
- QTc interval at baseline of ≥470 msec.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part B - 24-Hour Exposure Cohort
Participants receive orellanine (ONC175) as a 30 minute intravenous infusion once during each 28 day treatment cycle. Hemodialysis is performed the day before the infusion and again approximately 24 hours after the infusion to define the exposure period, as orellanine is eliminated primarily through dialysis. Participants will continue their regular hemodialysis schedule throughout the cycle. |
Orellanine administered intravenously |
|
Eksperimentel: Part B - 72 Hour Exposure Cohort
Participants receive orellanine (ONC175) as a 30 minute intravenous infusion once during each 28 day treatment cycle. In this cohort, hemodialysis is performed on the morning of the infusion, and additional hemodialysis sessions occur on the following days. Replacement doses of orellanine may be administered on the days after the initial infusion, depending on the assigned dose level. Hemodialysis is performed approximately 72 hours after the initial infusion to define the extended exposure period, as orellanine is eliminated primarily through dialysis. |
Orellanine administered intravenously |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Maksimal tolerabel dosis af orellanin
Tidsramme: Gennem studieafslutning, cirka 1 år
|
Gennem studieafslutning, cirka 1 år
|
|
Uønskede hændelser og laboratorieabnormiteter som klassificeret af NCI CTCAE v5.0.
Tidsramme: Gennem studieafslutning, cirka 1 år
|
Gennem studieafslutning, cirka 1 år
|
|
Ændringer i arterielle blodtryksmålinger
Tidsramme: Gennem studieafslutning, cirka 1 år
|
Gennem studieafslutning, cirka 1 år
|
|
Ændringer i pulsmålinger
Tidsramme: Gennem studieafslutning, cirka 1 år
|
Gennem studieafslutning, cirka 1 år
|
|
Ændringer i respirationsfrekvensmålinger
Tidsramme: Gennem studieafslutning, cirka 1 år
|
Gennem studieafslutning, cirka 1 år
|
|
Ændringer i temperaturmålinger
Tidsramme: Gennem studieafslutning, cirka 1 år
|
Gennem studieafslutning, cirka 1 år
|
|
Ændringer i fysiske undersøgelsesresultater
Tidsramme: Gennem studieafslutning, cirka 1 år
|
Gennem studieafslutning, cirka 1 år
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Effekten af orellanin baseret på tid til tumorrespons
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Effektiviteten af orellanin baseret på bedste overordnede respons
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Areal under kurven ekstrapoleret til uendeligt
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Delvis areal under kurven
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Dosis proportionalitet
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Tid til maksimal plasmakoncentration
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Maksimal plasmakoncentration
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Total kropsklaring
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Distributionsvolumen
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
|
Terminal halveringstid
Tidsramme: Gennem studieafslutning, cirka 1 år.
|
Gennem studieafslutning, cirka 1 år.
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
- Buvall L, Hedman H, Khramova A, Najar D, Bergwall L, Ebefors K, Sihlbom C, Lundstam S, Herrmann A, Wallentin H, Roos E, Nilsson UA, Johansson M, Tornell J, Haraldsson B, Nystrom J. Orellanine specifically targets renal clear cell carcinoma. Oncotarget. 2017 Jul 25;8(53):91085-91098. doi: 10.18632/oncotarget.19555. eCollection 2017 Oct 31.
- Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global Burden of Urologic Cancers, 1990-2013. Eur Urol. 2017 Mar;71(3):437-446. doi: 10.1016/j.eururo.2016.10.008. Epub 2016 Oct 28.
- Hedman H, Holmdahl J, Molne J, Ebefors K, Haraldsson B, Nystrom J. Long-term clinical outcome for patients poisoned by the fungal nephrotoxin orellanine. BMC Nephrol. 2017 Apr 3;18(1):121. doi: 10.1186/s12882-017-0533-6.
- Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Curr Oncol Rep. 2017 Apr;19(4):27. doi: 10.1007/s11912-017-0583-8.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Patologiske processer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Kronisk sygdom
- Sygdomsegenskaber
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplastiske processer
- Nyreinsufficiens
- Urologiske neoplasmer
- Karcinom
- Nyreinsufficiens, kronisk
- Patologiske tilstande, tegn og symptomer
- Neoplasma Metastase
- Karcinom, nyrecelle
- Nyresvigt, kronisk
- Nyre-neoplasmer
- orellanin
Andre undersøgelses-id-numre
- ONC001-CL-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Pursuant to relevant data protection and privacy legislation, patients will authorize the collection, use and disclosure of their study data by the investigator and by those persons who need that information for the purposes of the study.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .